Abstract
The novel coronavirus disease (COVID-19) caused by the coronavirus SARS-CoV-2, and leads to intense respiratory distress syndrome, has influenced more than nineteen million individuals around the world, coming about in 0.7 million passings as of Eminent 2020. The truth that the infection employments angiotensin-converting protein 2 as a receptor for entering the target cell, and the tall predominance of hypertension and other cardiovascular illnesses among patients with COVID-19, have caused genuine dialogs on the administration of such patients. This agreement of specialists from the Uzbek Restorative Society for Blood vessel Hypertension analyzed the existing information on the relationship between COVID-19 and hypertension, the pathophysiological angles of the entrance of the infection into target cells and the utilize of renin-angiotensin-aldosterone framework inhibitors in patients with hypertension and COVID-19.